Live webinar discussing liquid biopsy for cancer diagnostics and therapeutic monitoring
21 October 2020
Discussion around the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.
The application of plasma samples bearing circulating tumor DNA (ctDNA) as a surrogate for solid tumor biopsy is an area of significant research and clinical interest. Genomic aberrations associated with ctDNA has been demonstrated to mirror the solid tumor mutational landscape and has the potential for early diagnosis of cancer as well as monitoring and tracking biomarkers associated with residual disease and/or recurrence.
Despite this promise, there are still open questions regarding the best way to implement liquid biopsy approaches in the clinical setting. Our panel brings together academic, clinical, and industry experts in liquid biopsy technologies who will describe the applications of this technique and discuss its benefits and shortcomings in the context of cancer disease management.
The panel includes:
Ed Schurring, PhD (Professor of Molecular Oncological Pathology, University of Groningen
Sandi Deans, PhD (Consultant Clinical Scientist and Director GenQA
Claudia Vollbrecht, PhD (Institute of Pathology, Charité – Universitätsmedizin Berlin